HESTER BIOSCIENCES LTD.

Hester Biosciences Ltd has launched a dedicated digital microsite for its 39th Annual Report for FY 2025-26. This interactive and user-friendly platform aims to enhance accessibility and stakeholder engagement. Key features include mobile-friendly navigation, interactive presentations of financial and operational highlights, and convenient download/sharing options. This initiative aligns with the company's digital transformation and sustainability goals.

Hester Biosciences Ltd announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. Standalone revenue saw a 14% increase to ₹726.60 million, with profit after tax (PAT) rising by 88% to ₹147.11 million. This growth was driven by a strong performance in the Poultry Healthcare Division, which increased revenues by 48%, and improved gross profit margins to 78%. Consolidated revenues, however, decreased by 8% to ₹841.05 million, primarily due to lower revenues from Nepal and Africa operations. Despite the revenue dip, consolidated PAT surged by 459% to ₹967.32 million, largely influenced by an exceptional gain of ₹853.49 million from the amendment of a Gates Foundation loan at Hester Africa. The company remains focused on strengthening its biologicals portfolio and expanding market penetration.

Hester Biosciences Ltd announced its unaudited standalone and consolidated financial results for the quarter ended 30 June 2026. The Board of Directors approved the results in a meeting held on 30 July 2026. The company reported total income of ₹2,997.71 million and a profit after tax of ₹521.00 million for the quarter. The results also include segment-wise performance for Poultry Healthcare and Animal Healthcare, with Poultry Healthcare contributing ₹618.16 million in revenue and ₹245.19 million in segment results for the quarter. The company will publish extracts of the results in newspapers as per SEBI regulations.

Hester Biosciences' consolidated Q1 FY27 profit surged 459% YoY to ₹96.73 Cr, but almost all of that is non-operating: a ₹85.35 Cr exceptional accounting gain from Hester Africa's Gates Foundation loan being restructured (principal cut from USD 12 million to USD 5 million, accrued interest waived, and the balance made interest-free) inflated the headline. Strip that out and consolidated PAT was ₹11.38 Cr, down ~34% YoY (adjustedPatYoYPct) and ~16% QoQ — the number that reflects underlying operations. Consolidated revenue itself fell 8% YoY (down 23% QoQ) to ₹77.24 Cr. Standalone tells a materially better story — revenue +14% YoY to ₹72.66 Cr and PAT +88% YoY to ₹14.71 Cr — because it excludes the deeper Animal Healthcare drag sitting in the international subsidiaries; the two bases diverge by well over 3% on growth and neither is 'wrong', they measure different perimeters. The divergence traces to segments. Poultry Healthcare grew 48% YoY standalone (₹61.77 Cr) and 47.5% YoY consolidated (₹62.13 Cr) on higher institutional business and traction in the FY26-launched feed-supplement/disinfectant range, lifting standalone gross margin to 78% from 69% and EBITDA margin to ~36% from ~21% a year ago. Animal Healthcare moved the opposite way: consolidated segment revenue nearly halved YoY to ₹15.11 Cr from ₹41.98 Cr (also down from ₹35.39 Cr last quarter), and the segment swung to a loss both standalone (-₹0.85 Cr vs +₹3.53 Cr a year ago) and consolidated (-₹4.19 Cr vs +₹13.21 Cr). Tax expense of ₹4.95 Cr moved barely from the ₹4.56 Cr current-tax line despite the ten-fold jump in reported PBT, confirming the Gates Foundation gain was untaxed — a marker that it's a genuine one-off, not a recurring cash item. Management's May 2026 call had projected an Animal Healthcare recovery 'starting in the upcoming quarter' after a year of tender delays, while sustaining Poultry's run; on the numbers, the Poultry half held but the Animal Healthcare recovery did not — the division got worse, with today's press release attributing the consolidated revenue decline to continued institutional-order timing variability in Nepal and 'delays in tender execution rather than any change in the underlying demand' in Africa. That is a miss against the specific catalyst management had flagged, even as the group booked a favourable balance-sheet outcome from the Africa loan renegotiation. No formal analyst consensus for this print could be located, so the read here is against the company's own prior guidance rather than street numbers. Separately, on 9 July 2026 — after this quarter closed, in Q2 FY27 — Hester sold an 11% stake in Texas Lifesciences for ₹2.3 Cr, continuing the portfolio-pruning around TLPL that began with last year's 43.81% divestment (TLPL deconsolidated from 27 March 2026); it does not affect this quarter's P&L.

Hester Biosciences Ltd announced that both the National Stock Exchange (NSE) and BSE Limited have issued their No-Objection Certificates (NOCs) for the re-classification application filed on May 19, 2026. The company received approval letters dated July 24, 2026, from NSE and BSE, granting their no-objection for re-classifying Mr. Ravin Gandhi and Ms. Bela Gandhi from the Promoter Group to the Public category, in accordance with Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has been requested to ensure compliance with subsequent disclosures related to this reclassification.

Hester Biosciences Ltd has announced that its Board of Directors will convene on Thursday, July 30, 2026. The primary agenda item for this meeting is to consider and approve the unaudited standalone and consolidated financial results for the quarter that concluded on June 30, 2026. This announcement is made in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has formally notified the BSE of this upcoming board meeting.

Hester Biosciences Ltd has divested its entire remaining 11% equity stake in Texas Lifesciences Private Limited (TLPL), comprising 543,248 equity shares. The sale was executed on July 8, 2026, to existing shareholders of TLPL for an aggregate consideration of INR 23 million. Following this transaction, Hester Biosciences no longer holds any equity investment in TLPL, marking a complete exit from its shareholding in the subsidiary. This disclosure is made in compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Hester Biosciences Ltd has issued a corrigendum to its 39th Annual General Meeting (AGM) notice. The correction rectifies a typographical error in the Explanatory Statement regarding the re-appointment of an Executive Director. The gross salary mentioned was incorrectly stated as INR 8.40 lakh per month and has now been corrected to INR 10 lakh per month. This adjustment aligns with the remuneration terms previously approved by the Board of Directors. The AGM is scheduled for July 21, 2026, via Video Conference/Other Audio Visual Means.

Hester Biosciences Ltd has announced the closure of its trading window for dealing in equity shares. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations and the company's internal code of conduct. The trading window will be shut from July 1, 2026, and will reopen 48 hours after the financial results for the quarter ended June 30, 2026, are made public. This measure is standard practice to prevent insider trading during periods when material non-public information may be available.

Hester Biosciences Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026. The report, filed as per SEBI regulations, details the company's operations, employee data, and market presence. Hester Biosciences is primarily engaged in the manufacturing and trading of veterinary vaccines and health products, contributing 100% to its turnover. The company serves both domestic and international markets, with exports accounting for 11% of its total turnover. The report also provides data on its workforce, including permanent employees and workers, and highlights the participation of women in its board and management.